Document:

Exhibit
10.1

 

CONVERTIBLE
PROMISSORY NOTE

THIS
NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE
SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
COVERING THIS NOTE OR SUCH SHARES UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR THE DELIVERY OF AN OPINION OF COUNSEL
THAT SUCH REGISTRATION IS NOT REQUIRED. THIS NOTE IS ALSO SUBJECT TO RESTRICTIONS ON TRANSFER.

REGEN
BIOPHARMA, INC.

	Issue Date: January 24 2018	 	Principal Amount:

1. Terms.
For value received, the Regen BioPharma, Inc., a Nevada corporation (the "Company") hereby absolutely and unconditionally
promises to pay to the order of __________________________(the "Lender") ON DEMAND AT ANY TIME AFTER December 6, 2020
(the "Maturity Date"), the principal amount of Twenty Five thousand dollars ($25,000) and interest on the whole amount
of said principal sum outstanding and remaining from time to time unpaid (the "Note"), commencing from the date hereof
and continuing until payment in full of this Note or conversion as hereinafter provided, at an annual rate equal to ten percent
(10%) simple interest. Interest shall be payable quarterly upon demand or upon conversion pursuant to Section 2 hereunder. Interest
shall be computed on the basis of the actual number of days elapsed divided by 365. Principal and interest shall be payable in
lawful money of the United States of America, at the principal place of business of the Lender or at such other place as the Lender
may have designated from time to time in writing to the Company.

2. Conversion.

2.1
Conversion Right. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid
principal amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue
Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed
or reclassified at the conversion price (the "Conversion Price") determined as provided herein (a "Conversion").

The Lender
shall have the right to convert one hundred percent (100%) of the Principal Amount and any accrued interest commencing as of the
date which is the earlier of:

	(i)		One day subsequent to the execution of an agreement to a transaction whose completion
would result in a "Change of Control" of the Company. For purposes of this Note, a Change of Control shall be defined
as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer
of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors
immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors
of the surviving entity following the closing of such transaction.

	(ii)		One day subsequent to the execution of an agreement
to a transaction whose completion would result in a "Change of Control" of KCL Therapeutics, Inc. For purposes of this
Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially
all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which
the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute
a majority of the Board of Directors of the surviving entity following the closing of such transaction.

	(iii)		One day subsequent to the commencement, in compliance
with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company's outstanding equity
securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities
("Tender Offer").

	(iv)		One day subsequent to the closing of a Transaction Event:

"Transaction Event" shall mean either of:

(a) The
sale by the Company or by KCL Therapeutics, Inc. of the Company's proprietary NR2F6 intellectual property to an unaffiliated third
party, or,

(b) The granting
of a license by the Company or by KCL Therapeutics, Inc. to an unaffiliated third party granting that unaffiliated third party
the right to develop and/or commercialize the Company's proprietary NR2F6 intellectual property.

	(v)		That date which is twenty four (24) months subsequent to the date of execution of
this Note.

The number of
shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the principal amount of
this Note to be converted (the "Conversion Amount") by the applicable Conversion Price as defined in this Section 2
then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of
Conversion"), delivered to the Company by the Lender on such conversion date (the "Conversion Date").

2.2 Conversion Price. The
"Conversion Price" shall be defined as the lower $0.025 per share, or, a 75% discount to the closing price of the Common
Stock on the Over-the-Counter Bulletin Board on the trading day immediately prior to the date that a Notice of Conversion is submitted
pursuant to Section 2.3. or, if the Over-the-Counter Bulletin Board is not the principal trading market for such security, the
closing price of such security on the principal securities exchange or trading market where such security is listed or traded on
the trading day immediately prior to the date that a Notice of Conversion is submitted pursuant to Section 2.3. or, if no closing
bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers
for such security that are listed in the "pink sheets" by the National Quotation Bureau, Inc. on the trading day immediately
prior to the date that a Notice of Conversion is submitted pursuant to Section 2.3.

2.3 Method of Conversion.
Subject to Section 2.1, this Note may be converted by the Lender by submitting to the Company a Notice of Conversion by facsimile,
e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 5:00 p.m., New York, New York time.
The Lender shall not be required to physically surrender this Note to the Company unless the entire unpaid principal amount of
this Note is so converted. The Lender and the Company shall maintain records showing the principal amount so converted and the
dates of such conversions so as not to require physical surrender of this Note upon each such conversion. In the event of any dispute
or discrepancy, such records of the Company shall, prima facie, be controlling and determinative in the absence of manifest error.
Notwithstanding the foregoing, if any portion of this Note is converted as aforesaid, the Lender may not transfer this Note unless
the Lender first physically surrenders this Note to the Company, whereupon the Company will forthwith issue and deliver upon the
order of the Lender a new Note of like tenor, registered as the Lender (upon payment by the Lender of any applicable transfer taxes)
may request, representing in the aggregate the remaining unpaid principal amount of this Note.

Upon
receipt by the Company from the Lender of a facsimile transmission, e-mail, or other reasonable means of communication of a Notice
of Conversion meeting the requirements for conversion, the Company shall issue and deliver or cause to be issued and delivered
to or upon the order of the Lender certificates for the Common Stock issuable upon such conversion within ten (10) business days
after such receipt. Upon receipt by the Company of a Notice of Conversion, the Lender shall be deemed to be the Lender of record
of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest
on this Note shall be reduced to reflect such conversion. All rights with respect to the portion of this Note being so converted
shall forthwith terminate except the right to receive the Common Stock or other securities as herein provided on such conversion.
In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Company is participating
in the Depository Trust Company ("DTC") Fast Automated Securities Transfer ("FAST") program, upon request of
the Lender, the Company shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable
upon conversion to the Lender by crediting the account of Lender's Prime Broker with DTC through its Deposit Withdrawal Agent Commission
("DWAC") system.

2.4
Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless
(i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Company or its transfer agent
shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions
of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration or 

(iii)
such shares are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule 144") or (iv) such
shares are transferred to an "affiliate" (as defined in Rule 144) of the Company who agrees to sell or otherwise transfer
the shares only in accordance with this Section 2.5 and who is an Accredited Investor as the term Accredited Investor is defined
in Rule 501 of Regulation D, promulgated under the Act.

Subject
to the removal provisions set forth below, until such time as the shares of Common Stock issuable upon conversion of this Note
have been registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for shares of issuable upon conversion of this Note
that has not been so included in an effective registration statement or that has not been sold pursuant to an effective registration
statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

"NEITHER THE
ISSUANCE OR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF
COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER
SAID ACT."

The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope
customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock
may be made without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company
or its transfer agent with reasonable assurances that the Common Stock issuable upon conversion of this Note (to the extent such
securities are deemed to have been acquired on the same date) can be sold pursuant to Rule 144 or (iii) in the case of the Common
Stock issuable upon conversion of this Note, such security is registered for sale by under an effective registration statement
filed under the Act or (iv) otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as
of a particular date that can then be immediately sold.

2.5
Reverse Stock Splits. If the number of shares of Common Stock outstanding at any time while this Note is outstanding is decreased
by a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the Conversion
Price shall be appropriately increased so that the number of shares of Common Stock issuable on conversion hereof shall be decreased
in proportion to such decrease in outstanding shares.

2.6
Stock Dividends and Stock Splits. If the Company, at any time while this Note is outstanding subdivides outstanding shares
of Common Stock into a larger number of shares then the Conversion price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such
event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event

 

3. Payment.

 

WIRE INSTRUCTIONS:

 

4. Prepayment.
Notwithstanding anything to the contrary contained herein, the Company shall have the right, exercisable on not less than ten
(10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding
principal and accrued interest. Any notice of prepayment hereunder shall be delivered to the Lender at its registered addresses
and shall state that the Company is exercising its right to prepay the Note and the date of prepayment, which shall be not more
than ten (10) Trading Days from the date of the prepayment notice. Upon receipt of a prepayment notice, Lender shall have the
right, but not the obligation, to accelerate the conversion period specified in Section 2.1 and convert that portion of the outstanding
principal balance which is subject to prepayment to Common Shares as provided for in Section 2.

5. Warrant
Coverage. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the
remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares
it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants
shall have a strike price of $0.025 per share. See Exhibit B (incorporated into this Note) for instructions on completing the
Exercise of Warrants document.

6. Events
of Default.

6.1
The following shall constitute events of default (individually an "Event of Default"):

(a)        
default in the payment, when due or payable, of an obligation to pay interest or principal under this Note, which default is not
cured by payment in full of the amount due within thirty (30) days from the date that the Lender receives notice of the occurrence
of such default;

(b)  
filing of a petition in bankruptcy or the commencement of any proceedings under any bankruptcy laws by or against the Company,
which filing or proceeding, is not dismissed within ninety (90) days after the filing or commencement thereof; or 

(c) failure
of the Company to comply in any way with the terms, covenants or conditions contained in this Note.

6.2 If
an Event of Default shall occur and be continuing, the Lender may, at its option, declare this Note to be immediately due and payable
without further notice or demand, whereupon this Note shall become immediately due and payable without presentment, demand or protest,
all of which are hereby waived by the Company.

7. Transfer
of Note. This Note may not be transferred or assigned other than a transfer or assignment to an Affiliate of the Lender. As
used herein, the term "Affiliate" means an entity that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the Lender.

8. Certain
Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any other formalities
of any kind.

9. Amendment,
Modification or Termination. This Note may only be modified, amended, or terminated (other than by payment in full) by an
agreement in writing signed by the Company and the Lender. No waiver of any term, covenant or provision of this Note shall be
effective unless given in writing by the Lender.

10. Governing
Law. This Note and the obligations of the Company hereunder shall be governed by and interpreted and determined in accordance
with the laws of the State of California (excluding the laws and rules of law applicable to conflicts or choice of law).

 

IN WITNESS
WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

	REGEN BIOPHARMA INC	 	 
	 	 	 
	/s/ David R. Koos 	 	 
	David R. Koos, CEO	 	 
	 	 	 
	1/24/ 2018	 	 

 

    	 	1	 

     

    

 

EXHIBIT
A

NOTICE
OF CONVERSION

The undersigned hereby elects to convert $
___________________________ principal amount and ________________ accrued interest of the Note into that number of shares of
Common Stock to be issued pursuant to the conversion of the Note as set forth below of REGEN BIOPHARMA, INC. according to the
conditions of the convertible note of the Company dated as of December 20, 2017 as of the date written below.

Date of Conversion: 

	Applicable Conversion Price	 	 
	(Attach Bloomberg price documentation)	 
	Number of Shares of Common Stock to be Issued Pursuant to Conversion of Note:	 	 
	 	 	 
	Amount of Principal Balance Due Remaining Under the Note After This Conversion:	 	 

Checked box corresponds to applicable instructions:

The Borrower shall electronically
transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with
DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

 

	 	Name of DTC Prime Broker:	 	 
	 	Account Number	 	 

[1 The undersigned hereby
requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below in the
name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

 

	 	Name:	 	 
	 	Address:	 	 
	 	 	 	 
	 	 	 	 
	 	Phone:	 	 

 

	 	 	 	 
	Name	 	Date	 
	Title	 	 	 

 

    	 	2	 

     

    

 

EXHIBIT
B

COMMON STOCK PURCHASE WARRANT

REGEN BIOPHARMA, INC.

THIS WARRANT AND THE SHARES
ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND
THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION.

THIS
COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, Lender is entitled, solely upon the
terms and subject to the limitations on exercise and the conditions hereinafter set forth, to subscribe for and purchase from the
Company, shares of common stock of the Company (the "Warrant Shares"). The purchase price of one Warrant Share under
this Warrant shall be equal to the $0.025 per Warrant Share ("Exercise Price").

 

1.
In the event that Company shall exercise Company's rights pursuant to Section 4 of the Note ("Prepayment Clause") , Lender
shall be entitled , on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have
been prepaid by the Company("Prepayment Date") , to subscribe for and purchase from the Company up to that number of
Warrant Shares at the Exercise Price per Share equivalent to that one tenth of that number of Common Shares that Lender would have
been entitled to be issued had Lender exercised Lender's Conversion Right pursuant to Section 2.1 of the Note as of the Prepayment
Date.

 

2.
In the event that, as of the Maturity Date, part of the outstanding and unpaid principal amount of this Note and any Accrued Interest
remains outstanding, Lender shall be entitled , on or prior to the close of business on the three (3) month anniversary of the
Maturity Date , to subscribe for and purchase from the Company up to that number of Warrant Shares at the Exercise Price per Share
equivalent to that one tenth of that number of Common Shares that Lender would have been entitled to be issued had Lender exercised
Lender's Conversion Right pursuant to Section 2.1 of the Note as of the Maturity Date.

 

3.
If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3 shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification

 

4. Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, from and after the initial exercise
date, and then at any time, by delivery to the Company (or such other office or agency of the Company as it may designate by
notice in writing to Lender at the address of the Lender appearing on the books of the Company) of a duly executed facsimile
or emailed copy of the Notice of Exercise form annexed hereto and delivery of the aggregate Exercise Price for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer

 

5.
Warrant Shares purchased hereunder will be delivered to Holder within 10 business days of Notice of Exercise.

 

6. The
Warrant Shares may not be sold or transferred unless (i) such shares are sold pursuant to an effective registration statement
under the Act or (ii) the Company or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall
be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to
be sold or transferred may be sold or transferred pursuant to an exemption from such registration or (iii) such shares are sold
or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule 144") or (iv) such shares are transferred
to an "affiliate" (as defined in Rule 144) of the Company who agrees to sell or otherwise transfer the shares only in
accordance with this Section 6 and who is an Accredited Investor as the term Accredited Investor is defined in Rule 501 of Regulation
D, promulgated under the Act. Subject to the removal provisions set forth below, until such time as the Warrant Shares have been
registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for Warrant Shares that have not been so included
in an effective registration statement or that have not been sold pursuant to an effective registration statement or an exemption
that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

 

"NEITHER
THE ISSUANCE OR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN
THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)
AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT."

The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope customary
for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such securities may be made
without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company or its transfer
agent with reasonable assurances that the Warrant Shares can be sold pursuant to Rule 144 or (iii) such security is registered
for sale by under an effective registration statement filed under the Act or (iv) otherwise may be sold pursuant to Rule 144 without
any restriction as to the number of securities as of a particular date that can then be immediately sold.

 

7.
The Lender shall not be required to physically surrender this Warrant to the Company. If the Lender has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, this Warrant shall automatically be cancelled without the
need to surrender the Warrant to the Company for cancellation.

 

8.
This Warrant may not be transferred or assigned other than a transfer or assignment to an Affiliate of the Lender. As used herein,
the term "Affiliate" means an entity that directly, or indirectly through one or more intermediaries, controls, or is
controlled by, or is under common control with, the Lender.

 

9. FORM
OF WARRANT NOTICE

NOTICE
OF EXERCISE

TO: REGEN
BIOPHARMA, INC.

The
undersigned hereby elects to purchase_____________ Warrant Shares of the Company pursuant to
the terms of the Warrant issued in connection with that Convertible Note in the amount of _______
by and between________ and the Company dated______ and maturing______ , 2020 and tenders herewith payment of the exercise
price in full, together with all applicable transfer taxes, if any.

Please issue a certificate
or certificates representing said Warrant Shares in the name of the undersigned. The undersigned is an "accredited investor"
as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE]

Name:

Date:Exhibit
10.2

 

THIS
UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation
(the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”),
a _______ whose address is _____________. 

WHEREAS:

The
Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions
set forth herein.

The
Company desires to issue and sell Units to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE,
IT IS AGREED AS FOLLOWS

	 	1.	Units

Each
Unit shall consist of one (1) share of common stock of the Company and one (1) share of the Series A Preferred Stock of the Company

	 	2.	Purchase
    Price

The
purchase price per Unit ( “Purchase Price”), payable in US Dollars, shall be 2 cents per unit.(Each Unit consists
of one (1) share of common stock of the Company and one (1) shares of the Series A Preferred Stock of the Company)

	 	3.	Form
    of Payment

 

The
Purchaser shall pay the Purchase Price per Unit multiplied by that number of Units Purchased by wire transfer of immediately available
funds to the Company

	WIRE
    INSTRUCTIONS:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

	 	4.	Issuance
    of Units

 

5
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Units
purchased 

	 	5.	Purchaser’s
    Representations and Warranties

 

	 	(a)	As
    of the date hereof, the Purchaser is purchasing the Units for its own account and not with a present view towards the public
    sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of
    1933, as amended ( the “Act”). 

 

	 	(b)	The
    Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under
    the Act

 

    	 	1	 

     

    

	 	(c)	The
    Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations
    of the Company and materials relating to the offer and sale of the Units which have been requested by the Purchaser or its
    advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information
    and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the
    Purchaser.

 

	 	(d)	Purchaser
    has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent,
    approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been
    obtained.

 

	 	(e)	The
    execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach
    of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach
    of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement,
    or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.

 

	 	6.	Company’s
    representations and warranties

 

	 	(a)	Company
    is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has
    the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
    approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been
    obtained. 

 

	 	(b)	The
    execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach
    of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach
    of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement,
    or instrument to which the Company is a party, or by which Company is or may be bound. 

 

	 	7.	Restricted
    Securities Acknowledgement

 

Purchaser
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Act , and
shall contain the following restrictive legend:

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

	 	8.	Entire
    Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

	 	9.	Governing
    Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

IN
WITNESS WHEREOF, the parties have hereunto executed this Agreement on the 26nd day of January 2018.

	By:
	 
	Company
	 
	 
	 
	David
    Koos, CEO
	Regen
    Biopharma, Inc.
	 
	 
	 
	 
	Purchaser
	By:
	Its:
	Date:1/26/2018
	 
	Number
    of Units Purchased:	2,500,000
	Total
    Purchase Price:	$50,000

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]